JOHNSON MATTHEY PHARMACEUTICAL MATERIALS DIVISION
LAUNCHES JOINT EFFORT AND NEW
IDENTITIES FOR BUSINESS UNITS

Johnson Matthey Pharmaceutical Materials Division will launch a worldwide joint marketing effort amongst its business units at CPhI 2004 coinciding with new market identities for three of these businesses. The new effort will focus on the combined power of the business units to provide cGMP API development and manufacturing solutions to the pharmaceutical industry worldwide. These services span the entire drug development pipeline and include specialized expertise in controlled drug handling and manufacturing.

The launch of the new market identities coincides with the effort to further enhance the cohesive network formed by the combined units within Johnson Matthey’s Pharmaceutical Materials Division. The division consists of four units: Johnson Matthey Pharma Services (formerly Pharm-Eco) Devens, MA, a leader in contract API manufacture (up to 500 gallons) and complex contract chemistry services as well as separations technologies; Johnson Matthey Pharmaceutical Materials – USA, West Deptford, NJ, which produces bulk API up to 2000 gallons specializing in controlled substances; Johnson Matthey Pharmaceutical Materials – Ireland (formerly Cascade Biochem Ltd.) Cork, Ireland, a leader in prostaglandin development and manufacture; and Johnson Matthey Macfarlan Smith, Edinburgh, Scotland, worldwide leader in controlled drug development and manufacture as well as natural product extraction.

This combined effort offers clients a single source for their entire API outsourcing needs around the world. Strong cGMP and regulatory compliance serve as the basis for process research, optimization, development, validation, scale-up, analytical methods development, custom synthesis, commercial manufacturing (mg – metric tons), natural product extraction, extensive experience in controlled drugs, handling of highly potent products, as well as full regulatory support in both Europe and the US.

News